CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Summary
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Conditions
Breast Neoplasms
Intervention
Aromatase Inhibitor(Femara or Arimidex)
Location
Korea University Anam Hopital
Seoul
Korea, Republic of
136-705
Status
Recruiting
Source
Korea University Anam Hospital
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00973505
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Fadrozole
A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.
Aminoglutethimide
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
Neoplasms, Ductal, Lobular, And Medullary
Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast.
Aromatase Inhibitors
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Clinical Trials
Many women with breast cancer who are treated with aromatase inhibitor medications develop aches and pains during treatment, and some develop numbness and tingling in their hands and feet....
Effect of Aromatase Inhibitors on Bones and Genes
The primary objective of this 2-year pilot project is to test the hypothesis that skeletal response to aromatase inhibitors is determined by polymorphisms of the CYP19 gene.
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibi...
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus. Recent...
Study of XL147 or XL765 in Combination With Letrozole in Subjects With Breast Cancer
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with letrozole (Femara) and of XL765 when given in combination with letrozole. After...
PubMed Articles
Natural Compounds with Aromatase Inhibitory Activity: An Update.
Several synthetic aromatase inhibitors are currently in clinical use for the treatment of postmenopausal women with hormone-receptor positive breast cancer. However, these treatments may lead to untow...
Drug safety evaluation of exemestane.
Introduction: Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibi...
The design and synthesis of a series of bicyclic ring containing dual aromatase-sulfatase inhibitors (DASIs) based on the aromatase inhibitor (AI) 4-[(4-bromobenzyl)(4H-1,2,4-triazol-4-yl)amino]benzon...
Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Increased intratumoral expression of aromatase, the key enzyme for estrogen biosynthesis, is predicted to be of critical importance in the development of breast cancer. Recently, several germline rear...
The age distribution of breast cancer patients in Korea, where most are less than 60 years of age and have recently entered menopause, differs from that in the West. The aim of this study was to eval...
